Effect of Administration of Lactobacillus casei Shirota on Sodium Balance in an Infant with Short Bowel Syndrome

D. C. A. Candy, Lucy Densham, Lilias S. Lamont, Marjorie Greig, Jonathan Lewis, Heidi Bennett, Mervyn Griffiths

Journal of Pediatric Gastroenterology and Nutrition · 2001 · 27 citations · 6 references

Concepts

Abstract

Small intestinal overgrowth, defined as increased numbers of bacteria in the upper gastrointestinal tract, is a common complication of short bowel syndrome (1,2). It has been suggested that effective treatment of small bowel overgrowth improved intestinal function in short bowel syndrome. Recurrent sepsis can complicate bacterial overgrowth, compromising liver function (3). If remedial factors predisposing the patient to intestinal overgrowth (subacute intestinal obstruction, fistulae, malnutrition, malabsorption, suppression of gastric acid production, antidiarrheal drugs) are absent, treatment entails broad-spectrum antibiotics. If corrective surgery (including resection of strictures and fistulae, bowel lengthening, and tapering procedures) is not feasible, relapse of symptoms (pain, distension, increasing diarrhea, acidosis, gastrointestinal bleeding) is to be expected when antibiotics are discontinued. Overgrowth with resistant microorganisms is likely if antibiotics are continued. Vanderhoof et al. (1) suggested other therapies, including intestinal flushes, regular toileting, saline enemas, stoma formation, and probiotics (viable bacteria that positively influence health). The patients administered probiotics (Lactobacillus plantarum 299V) and Lactobacillus GG (CAG Nutrition, Omaha, NE) seemed to improve. Immunosuppressants (sulfasalazine, steroids, cytotoxic agents) also have been used to control resultant intestinal inflammation. We report a case of short bowel syndrome after resection of all but 60 cm of proximal jejunum in which we have objective evidence of marked improvement in sodium absorption after the beginning of probiotic therapy. CASE REPORT A male infant was transferred on the second day of life to the Wessex Regional Centre for Paediatric Surgery, Southampton, U. K. with bile-stained vomiting and gross abdominal distension caused by anal atresia. Perineal anoplasty was performed but the patient's abdomen remained distended postoperatively. Necrotizing enterocolitis developed, necessitating resection of the ileum and colon and the fashioning of a jejunostomy. He was left with 60 cm of jejunum. The postoperative course was complicated by sepsis, which necessitated inotropic support, and renal failure, which necessitated hemofiltration and hypoxic–ischemic encephalopathy. At 7 months of age, he underwent jejunal–rectal anastomosis. Gastrostomy was performed at 10 months of age to facilitate nutritional support. Nutritional care included parenteral nutrition (PN), expressed breast milk, and an extensively hydrolyzed casein-based formula (Pregestimil; Mead Johnson, Hounslow, U.K.). He underwent oral rehydration therapy and Na+ supplements to replace jejunostomy losses that were greater than 1 liter a day. Pharmacotherapy included administration of ranitidine to prevent hypersecretion of gastric acid in response to hypergastrinemia secondary to massive intestinal resection. Cisapride was administered because of excess vomiting of enteral feed. Phenobarbitone and ursodeoxycholic acid were administered to try to prevent PN-associated cholestasis. Presumed small bowel overgrowth was treated with rotating courses of trimethoprim and metronidazole. He required repeated courses of systemic antibiotics and antifungal agents for line sepsis. At 11 months of age, the patient was transferred from Pregestimil formula to amino acid-based Neocate (Scientific Hospital Supplies, Liverpool, U.K.). Stool output decreased sufficiently to be able to discontinue PN 23 days later. However, mean ± SEM random urine Na+ concentration of six samples taken while receiving Neocate and Na+ supplements (8 mmol · kg · day) was 8 ± 5 mmol/L (Table 1).TABLE 1: Urinary Na: Effect of Lactobacillus casei ShirotaJejunal effluent, when cultured, yielded a rich microbial flora, typical of fecal cultures. On the basis that this represented abnormal small bowel flora that could impair the function of his residual jejunum, it was decided to try probiotic therapy. He was started, at 12 months of age, on 15 ml Lactobacillus casei Shirota (at least 1.5 × 109 viable lactobacilli) three times a day in flavored skim milk (Yakult UK, Acton, London, U.K.). The viable count of lactobacilli in the preparation was confirmed in our laboratory. Fortunately, L. casei Shirota was resistant to trimethoprim (1 mg/kg) administered as prophylaxis against urinary tract infection after damage to the left kidney sustained in the neonatal period. Microscopic examination of the patient's stool showed abundant lactobacilli 3 days after supplementation. Culture on MRS Agar (Oxoid, U.K.) supplemented with vancomycin and ciprofloxacin yielded lactobacilli; lactobacilli were absent from stool cultures obtained before supplementation. The mean ± SEM concentration of Na+ in six urine samples after beginning probiotic therapy was 92 ± 20 mol/l (Fig. 1;P < 0.001, paired t test). Stool frequency decreased from 12 to 4 per day. Improved Na+ balance provided the confidence to remove the central venous feeding catheter and discharge the patient.FIG. 1.: Effect of intragastric administration of Lactobacillus casei Shirota on urinary sodium (Na). Arrow indicates start of supplementation.Two years later, the patient continues to undergo probiotic therapy. His parents are understandably reluctant to discontinue probiotics, the dose of which is increased during episodes of acute diarrhea, associated with rotavirus, for which lactobacilli are effective therapy (4). He consumes a variety of normal foods supplemented with an elemental diet. He passes four stools a day but is able to avoid defecating at night. A more recent urinary Na+ concentration was 186 mmol/l and Na+ supplement was reduced. His height is in the 10th percentile, weight in the 3rd, and development is normal. DISCUSSION Although this child had 60 cm of residual small intestine, the site of the remaining intestine (proximal jejunum) mitigated against successful enteral feeding (5). A high output of water and electrolytes is to be expected in patients with a jejunostomy. Parenteral supplements of saline, magnesium, and calcium are often necessary. A high jejunostomy will require support with parenteral nutrition (6). This region of the intestine is the most permeable and hence osmotic diarrhea of greater than 1 L per 24 hours resulted from enteral feeding. The distal intestine, adapted for electrolyte conservation, had been resected. Loss of the ileum meant loss of adaptive capacity for macro-and micronutrient absorption, bile salt absorption, and the ileal brake which delays intestinal transit. Furthermore, the presence of varied fecal bacteria in the jejunal effluent indicated the presence of small intestinal overgrowth. In healthy persons, the proximal jejunal contents would have viable counts of bacteria of 103–104 per ml compared with greater 1011 in the colon (7). To our knowledge, this is the first report of objective improvement in human jejunal function after administration of a probiotic. We used urinary Na+ excretion as a surrogate for direct measurement of jejunal Na+ absorption. The subject's Na+ intake was administered in his enteral feeding via a gastrostomy by constant infusion over 24 hours. No change in Na+ intake or other therapy occurred at the time of introduction of the probiotic. Therefore, changes in urinary Na+ concentration reflected changes in jejunal Na+ absorption in the absence of any other alterations in extrarenal Na+ losses. The anatomy of the intestinal resection may have enhanced the possibility of benefit from probiotic therapy. There was no reservoir of colonic microorganisms to colonize the jejunum in a retrograde fashion and compete with the intragastrically administered lactobacilli. Lactobacilli could not be detected on culture of the jejunal effluent before supplementation but were present afterward. Repeated examination of jejunal fluid showed that, after administration of L. casei Shirota, the only microorganisms detectable on microscopy of a Gram stain of the fluid resembled lactobacilli. Improved tolerance of enteral feeding on transfer from extensively hydrolyzed casein-based to an amino acid based formula in children with short bowel syndrome has previously been reported (8). The authors hypothesized that the infants became allergic to the peptides derived from casein in the extensively hydrolyzed formula. This maneuver cannot explain the improvement in jejunal Na+ absorption that was temporally related to supplementation with lactobacilli. The transfer to an elemental diet was made 1 month before beginning probiotic therapy. The patient was still in negative Na+ balance while receiving Neocate and a Na+ supplement of 10 mmol · kg · d until 3 days after introducing lactobacilli. It is of interest to speculate how administration of L. casei Shirota may have improved jejunal function. Small bowel overgrowth may result in inflammatory enteropathy. The adherence of bacteria to the small intestine and subsequent production of cytotoxins, enzymes, and toxic metabolic by-products can damage the mucosa, both directly and indirectly, via bile salt deconjugation (7). Inhibition of the inflammatory response may be associated with an improvement in jejunal structure and function. Bacteria can compete with the host for substrates such as vitamin B12. Lactobacilli can inhibit the growth of pathogenic coliforms and anaerobes in the intestinal tract and therefore presumably the growth of similar species responsible for bacterial overgrowth (9). By adhering to the intestinal mucosa, lactobacilli can prevent colonization by more pathogenic bacteria. They also produce bactericidal compounds, such as short-chain fatty acids, and stimulate the protective intestinal immune system. Replacing the bacterial load in the small intestine with avirulent bacteria will reverse the adverse effects of bacterial overgrowth, outlined previously. A bacterial flora composed of lactobacilli will stimulate protective, immunoglobin A-mediated immunity rather than an inflammatory reaction. The use of probiotic therapy in short bowel syndrome has been limited by concerns that D-lactic acidosis would result. The absence of a colon in this patient, in which the bulk of fermentation would be expected to occur, may have partially protected him from this complication. The probiotic agent administered, L. casei Shirota, produces predominantly L-lactate (C. Shortt, personal communication, February 1999) and this will have minimized the load of D-lactate generated. Lactobacilli that produce only L-lactate should be tried in subjects with short bowel syndrome and D-lactic acidosis to determine whether probiotic therapy protects the patient from this complication. CONCLUSION Administration of L. casei Shirota to a child with short bowel syndrome was associated with prompt and dramatic improvement in Na+ balance. The result of supplementation with lactobacilli in this case has stimulated us to investigate the role of probiotic therapy in the treatment of children with short bowel syndrome and other gastrointestinal disorders. Acknowledgment: The authors thank Yakult UK Ltd., Acton, London, for their contribution to covering the cost of microbiology consumables.

References

6